This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Argilés, A. Articles by Atkins, R. C. Search for Related Content PubMed PubMed Citation Articles by Argilés, A. Articles by Atkins, R. C.

Epidermal Growth Factor and Transforming Growth Factor Stimulate or Inhibit Proliferation of a Human Renal Adenocarcinoma Cell Line Depending on Cell Status: Differentiation of the Two Pathways by G Protein Involvement¹

Department of Nephrology, Monash Medical Centre, Clayton Road 3168, Victoria, Australia

Transforming growth factor production by renal tumors, acting through the epidermal growth factor receptor, has been implicated in malignant transformation by studies which compared gene expression in neoplastic and normal human tissue. We sought confirmation of this hypothesis by measuring the growth responses of a human renal tumor cell line to the addition of epidermal growth factor and transforming growth factor . Surprisingly, it was found that both growth factors could induce either mitogenic or inhibitory signals depending on the growth status of the cultures. Confluent cultures were stimulated by both growth factors, and nonconfluent cultures were inhibited, as determined by thymidine incorporation, cell cycle analysis, and direct cell counting. These signals appear to use different transduction pathways, as growth factor induced inhibition was reversed by Bordetella pertussis toxin (which affects G protein signaling), whereas the stimulatory effects were not reversed. Two clones isolated from these cells responded in the same manner as the main cell isolate. These data show that the same cell may display opposite responses to equivalent conentrations of the same growth factor, depending on the transduction pathway used after triggering by receptor occupancy of either ligand (epidermal growth factor or transforming growth factor ).

¹ Part of this study has been published in abstract form in the International Society of Nephrology meeting in Tokyo, 1990. A. A. was supported by a grant from the Spanish Ministerio de Educacion y Ciencia, Servicio de Formacion del personal investigador. N. K. was supported by Australian NH&MRC Grant 910260.

² Present address: LP8402 CNRS and Unit 249 INSERM, Centre de Recherches de Biochimie Macromoleculaire, Route de Mende, 34033 Montpellier Cedex, France.

³ To whom requests for reprints should be addressed.

Received 10/ 7/91. Accepted 6/ 9/92.

This article has been cited by other articles:

				D. Fliser, J. Novak, V. Thongboonkerd, A. Argiles, V. Jankowski, M. A. Girolami, J. Jankowski, and H. Mischak Advances in Urinary Proteome Analysis and Biomarker Discovery J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1057 - 1071. [Abstract] [Full Text] [PDF]

				Y. Z. Hui, A. E. Noffsinger, M. A. Miller, P. Hurtubise, and C. M. Fenoglio-Preiser Strong Epidermal Growth Factor Receptor Expression But Not HER2/neu Expression Correlates with Cell Proliferation in Anal Canal Carcinomas International Journal of Surgical Pathology, October 1, 1999; 7(4): 193 - 203. [Abstract] [PDF]

				T. J. Kottke, A. L. Blajeski, L. M. Martins, P. W. Mesner Jr., N. E. Davidson, W. C. Earnshaw, D. K. Armstrong, and S. H. Kaufmann Comparison of Paclitaxel-, 5-Fluoro-2'-deoxyuridine-, and Epidermal Growth Factor (EGF)-induced Apoptosis. EVIDENCE FOR EGF-INDUCED ANOIKIS J. Biol. Chem., May 28, 1999; 274(22): 15927 - 15936. [Abstract] [Full Text] [PDF]